Geniposide regulates insulin-degrading enzyme expression to inhibit the cytotoxicity of Aβ1-42 in cortical neurons

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 8, 2012, Pages 1045-1051

  Yin, Fei ^a   Zhang, Yonglan ^a,b   Guo, Lixia ^a   Kong, Shuzhen ^a   Liu, Jianhui ^a  

^a CHONGQING TECHNOLOGY AND BUSINESS UNIVERSITY   (China)

^b CHONGQING UNIVERSITY   (China)

Author keywords

amyloid (A ); Alzheimer's disease (AD); Glucagon like peptide 1 receptor (GLP 1R); Insulin degrading enzyme (IDE); Neuroprotection; Neurotoxicity

Indexed keywords

AMYLOID BETA PROTEIN; BACITRACIN; GENIPOSIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INSULINASE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; MALE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PROTEIN AGGREGATION; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; UPREGULATION; WESTERN BLOTTING;

AMYLOID BETA-PEPTIDES; ANIMALS; CEREBRAL CORTEX; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INSULYSIN; IRIDOIDS; MALE; NEURONS; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84874582683     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527311211080015     Document Type: Article

References (40)

1. Roychaudhuri, R.; Yang, M.; Hoshi, M. M.; Teplow, D.B. Amyloid beta-protein assembly and Alzheimer disease. J. Biol. Chem., 2009, 284, 4749-4753.
2. Killiany, R.J. Isn't amyloid more than just a marker for Alzheimer disease? Neurology, 2009, 73, 1174-1175.
3. Okura Y., Kohyama K., Park I. K., Matsumoto Y. Nonviral DNA vaccination augments microglial phagocytosis of beta-amyloid deposits as a major clearance pathway in an Alzheimer disease mouse model. J. Neuropathol. Exp. Neurol., 2008, 67, 1063-1071.
4. Brindle, N.; George-Hyslop, P.S. The genetics of Alzheimer's disease. Methods Mol. Med., 2000, 32, 23-43.
5. Tanzi R.E.; George-Hyslop, P.S.; Gusella, J.F. Molecular genetics of Alzheimer disease amyloid. J. Biol. Chem., 1991, 266, 20579-20582.
6. Savage M.J.; Trusko, S.P., Howland, D.S.; Pinsker, L.R.; Mistretta, S.; Reaume, A.G.; Greenberg, B.D.; Siman, R.; Scott, R.W. Turnover of amyloid beta-protein in mouse brain and acute reduction of its level by phorbol ester. J. Neurosci., 1998, 18, 1743-1752.
7. Dovey, H.F.; John, V.; Anderson, J.P.; Chen, L.Z.; de Saint Andrieu, P.; Fang, L.Y.; Freedman, S.B.; Folmer, B.; Goldbach, E.; Holsztynska, E.J.; Hu, K.L.; Johnson-Wood, K.L.; Kennedy, S.L.; Kholodenko, D.; Knops J.E.; Latimer, L.H.; Lee, M.; Liao, Z.; Lieberburg, I.M.; Motter, R.N.; Mutter, L.C.; Nietz, J.; Quinn, K.P.; Sacchi, K.L.; Seubert, P.A.; Shopp, G.M.; Thorsett, E.D.; Tung, J.S.; Wu, J.; Yang, S.; Yin, C.T.; Schenk, D.B.; May, P.C.; Altstiel, L.D.; Bender, M.H.; Boggs, L.N.; Britton, T.C.; Clemens, J.C.; Czilli, D.L.; Dieckman-McGinty, D.K.; Droste, J.J.; Fuson, K.S.; Gitter, B.D.; Hyslop, P.A.; Johnstone, E.M.; Li, W.Y.; Little, S.P., Mabry, T.E.; Miller, F.D.; Audia J.E. Functional gammasecretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem., 2001, 76, 173-181.
8. Thiele, T.E.; Seeley, R.J.; D'Alessio, D.; Eng, J.; Bernstein, I.L.; Woods, S.C.; van Dijk, G. Central infusion of glucagon-like peptide-1-(7-36) amide (GLP-1) receptor antagonist attenuates lithium chloride-induced c-Fos induction in rat brainstem. Brain Res., 1998, 801, 164-170.
9. Vekrellis, K.; Ye, Z.; Qiu, W.Q.; Walsh, D.; Hartley, D.; Chesneau, V.; Rosner, M.R.; Selkoe, D.J. Neurons regulate extracellular levels of amyloid beta-protein via proteolysis by insulin-degrading enzyme. J. Neurosci., 2000, 20, 1657-1665.
10. Seta, K.A.; Roth, R.A. Overexpression of insulin degrading enzyme: cellular localization and effects on insulin signaling. Biochem. Biophys. Res. Commun., 1997, 231, 167-171.
11. Wang, S.; Wang, R.; Chen, L.; Bennett, D.A.; Dickson, D.W.; Wang, D.S. Expression and functional profiling of neprilysin, insulin-degrading enzyme, and endothelin-converting enzyme in prospectively studied elderly and Alzheimer's brain. J. Neurochem., 115, 47-57.
12. Kurochkin, I.V. Insulin-degrading enzyme: embarking on amyloid destruction. Trends Biochem. Sci., 2001, 26, 421-425.
13. Zhao, Z.; Xiang, Z.; Haroutunian, V.; Buxbaum, J.D.; Stetka, B.; Pasinetti, G.M. Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. Neurobiol. Aging, 2007, 28, 824-830.
14. Farris, W.; Mansourian, S.; Chang, Y.; Lindsley, L.; Eckman, E.A.; Frosch, M.P.; Eckman, C.B.; Tanzi, R.E.; Selkoe, D.J.; Guenette, S. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc. Natl. Acad. Sci. U S A, 2003, 100, 4162-4167.
15. Leissring, M.A.; Farris, W.; Chang, A.Y.; Walsh, D.M.; Wu, X.; Sun, X.; Frosch, M.P.; Selkoe, D.J. Enhanced proteolysis of betaamyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron, 2003, 40, 1087-1093.
16. Perry, T.; Haughey, N.J.; Mattson, M.P.; Egan, J.M.; Greig, N.H. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J. Pharmacol. Exp. Ther., 2002, 302, 881-888.
17. Perry, T.; Greig N.H. Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr. Alzheimer Res. 2005, 2, 377-385.
18. During M.J.; Cao, L.; Zuzga, D.S.; Francis, J.S.; Fitzsimons, H.L.; Jiao, X.; Bland, R.J.; Klugmann, M.; Banks, W.A.; Drucker, D.J.; Haile, C.N. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat. Med., 2003, 9, 1173-1179.
19. Holst, J.J. The physiology of glucagon-like peptide 1. Physiol. Rev., 2007, 87, 1409-1439.
20. Liu, J.; Zheng, X.; Yin, F.; Hu, Y.; Guo, L.; Deng, X.; Chen, G.; Jiajia, J.; Zhang, H. Neurotrophic property of geniposide for inducing the neuronal differentiation of PC12 cells. Int. J. Dev. Neurosci., 2006, 24, 419-424.
21. Liu, J.; Yin, F.; Zheng, X.; Jing, J.; Hu, Y. Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway. Neurochem. Int., 2007, 51, 361-369.
22. Yin, F.; Liu, J.; Zheng, X.; Guo, L.; Xiao, H. Geniposide induces the expression of heme oxygenase-1 via PI3K/Nrf2-signaling to enhance the antioxidant capacity in primary hippocampal neurons. Biol. Pharm. Bull. 2010, 33, 1841-1846.
23. Yin, F.; Liu, J.H.; Zheng, X.X.; Guo, L.X. GLP-1 receptor plays a critical role in geniposide-induced expression of heme oxygenase-1 in PC12 cells. Acta. Pharmacol. Sin., 2010, 31, 540-545.
24. Liu, J.H.; Yin, F.; Guo, L.X.; Deng, X.H.; Hu, Y.H. Neuroprotection of geniposide against hydrogen peroxide induced PC12 cells injury: involvement of PI3 kinase signal pathway. Acta. Pharmacol. Sin., 2009, 30, 159-165.
25. Yin, F.; Liu, J.; Ji, X.; Wang, Y.; Zidichouski, J.; Zhang, J. Baicalin prevents the production of hydrogen peroxide and oxidative stress induced by Abeta aggregation in SH-SY5Y cells. Neurosci. Lett., 2011, 492, 76-79.
26. Yin, F.; Liu, J.; Ji, X.; Wang, Y.; Zidichouski, J.; Zhang, J. Silibinin: a novel inhibitor of Abeta aggregation. Neurochem. Int., 2011, 58, 399-403.
27. Negishi, T.; Ishii, Y.; Kyuwa, S.; Kuroda, Y.; Yoshikawa, Y. Inhibition of staurosporine-induced neuronal cell death by bisphenol A and nonylphenol in primary cultured rat hippocampal and cortical neurons. Neurosci. Lett., 2003, 353: 99-102.
28. Dahlgren, K.N.; Manelli, A.M.; Stine, W.B., Jr.; Baker, L.K.; Krafft, G.A.; LaDu, M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem., 2002, 277, 32046-32053.
29. Crouch, P.J.; Harding, S.M.; White, A.R.; Camakaris, J.; Bush, A.I.; Masters, C.L. Mechanisms of A beta mediated neurodegeneration in Alzheimer's disease. Int. J. Biochem. Cell Biol., 2008, 40, 181-198.
30. Coria, F.; Rubio, I.; Bayon, C. Alzheimer's disease, betaamyloidosis, and aging. Rev. Neurosci. 1994, 5, 275-292.
31. Qin, W.; Jia, J. Down-regulation of insulin-degrading enzyme by presenilin 1 V97L mutant potentially underlies increased levels of amyloid beta 42. Eur. J. Neurosci., 2008, 27: 2425-2432.
32. Yamazaki, M.; Chiba, K.; Mohri, T. Neuritogenic effect of natural iridoid compounds on PC12h cells and its possible relation to signaling protein kinases. Biol. Pharm. Bull., 1996, 19, 791-795.
33. Lee, P.; Lee, J.; Choi, S.Y.; Lee, S.E.; Lee, S.; Son, D. Geniposide from Gardenia jasminoides attenuates neuronal cell death in oxygen and glucose deprivation-exposed rat hippocampal slice culture. Biol. Pharm. Bull., 2006, 29, 174-176.
34. Li, Y.; Duffy, K.B.; Ottinger, M.A., Ray, B.; Bailey, J.A., Holloway, H.W.; Tweedie, D.; Perry, T.; Mattson M.P.; Kapogiannis, D.; Sambamurti, K.; Lahiri, D.K.; Greig, N.H. GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. J. Alzheimers Dis., 2010, 19, 1205-1219.
35. Perry, T.; Lahiri, D.K.; Sambamurti, K.; Chen D.; Mattson, M.P.; Egan, J.M.; Greig, N.H. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J. Neurosci. Res., 2003, 72, 603-612.
36. Selkoe, D.J. Physiological production of the beta-amyloid protein and the mechanism of Alzheimer's disease. Trends Neurosci., 1993, 16, 403-409.
37. Selkoe, D.J. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev., 2001, 81, 741-766.
38. Bertram, L.; Blacker, D.; Mullin, K.; Keeney, D.; Jones, J.; Basu, S.; Yhu, S.; McInnis, M.G.; Go, R.C.; Vekrellis, K.; Selkoe, D.J.; Saunders, A.J.; Tanzi R.E. Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. Science, 2000, 290, 2302-2303.
39. Ertekin-Taner, N.; Ronald, J.; Feuk, L.; Prince, J.; Tucker, M.; Younkin, L.; Hella, M.; Jain, S.; Hackett, A.; Scanlin, L.; Kelly, J.; Kihiko-Ehman, M.; Neltner, M.; Hersh, L.; Kindy, M.; Markesbery, W.; Hutton, M.; de Andrade, M.; Petersen, R.C.; Graff-Radford, N.; Estus, S.; Brookes, A.J.; Younkin, S.G. Elevated amyloid beta protein (Abeta42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene. Hum. Mol. Genet., 2005, 14, 447-460.
40. Cook, D.G.; Leverenz, J.B.; McMillan, P.J.; Kulstad, J.J.; Ericksen, S.; Roth, R.A.; Schellenberg, G.D.; Jin, L.W.; Kovacina, K.S.; Craft, S. Reduced hippocampal insulin-degrading enzyme in lateonset Alzheimer's disease is associated with the apolipoprotein Eepsilon4 allele. Am. J. Pathol., 2003, 162, 313-319.